JP7385474B2 - 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物 - Google Patents

非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物 Download PDF

Info

Publication number
JP7385474B2
JP7385474B2 JP2019551311A JP2019551311A JP7385474B2 JP 7385474 B2 JP7385474 B2 JP 7385474B2 JP 2019551311 A JP2019551311 A JP 2019551311A JP 2019551311 A JP2019551311 A JP 2019551311A JP 7385474 B2 JP7385474 B2 JP 7385474B2
Authority
JP
Japan
Prior art keywords
mpa
modified release
veterinary
composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019551311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510691A (ja
JP2020510691A5 (cg-RX-API-DMAC7.html
Inventor
マイケル クロツマン,
パドマジャ シヴァナンド,
ウェイン エイチ. アンダーソン,
ガヤトリ サティヤン,
Original Assignee
オカヴァ ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オカヴァ ファーマシューティカルズ, インコーポレイテッド filed Critical オカヴァ ファーマシューティカルズ, インコーポレイテッド
Publication of JP2020510691A publication Critical patent/JP2020510691A/ja
Publication of JP2020510691A5 publication Critical patent/JP2020510691A5/ja
Application granted granted Critical
Publication of JP7385474B2 publication Critical patent/JP7385474B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019551311A 2017-03-13 2018-03-13 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物 Active JP7385474B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762470806P 2017-03-13 2017-03-13
US62/470,806 2017-03-13
US201762503270P 2017-05-08 2017-05-08
US62/503,270 2017-05-08
PCT/US2018/022266 WO2018170022A2 (en) 2017-03-13 2018-03-13 Methods and compositions for delivering mycophenolic acid active agents to non-human mammals

Publications (3)

Publication Number Publication Date
JP2020510691A JP2020510691A (ja) 2020-04-09
JP2020510691A5 JP2020510691A5 (cg-RX-API-DMAC7.html) 2021-04-30
JP7385474B2 true JP7385474B2 (ja) 2023-11-22

Family

ID=61911669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019551311A Active JP7385474B2 (ja) 2017-03-13 2018-03-13 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物

Country Status (10)

Country Link
US (4) US11633378B2 (cg-RX-API-DMAC7.html)
EP (1) EP3595639A2 (cg-RX-API-DMAC7.html)
JP (1) JP7385474B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190131036A (cg-RX-API-DMAC7.html)
CN (1) CN110662533A (cg-RX-API-DMAC7.html)
AU (1) AU2018236225B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019019003A2 (cg-RX-API-DMAC7.html)
CA (1) CA3054817A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019010829A (cg-RX-API-DMAC7.html)
WO (1) WO2018170022A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010829A (es) 2017-03-13 2020-02-05 Okava Pharmaceuticals Inc Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos.
EP3846798A1 (en) * 2018-09-07 2021-07-14 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
US12701991B2 (en) 2021-08-18 2026-08-04 Texas Instruments Incorporated Integrated isolation capacitor with enhanced bottom plate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508959A (ja) 2001-10-17 2005-04-07 ノバルティス アクチエンゲゼルシャフト ミコフェノール酸またはミコフェノール酸塩を含む医薬組成物
JP2007507458A (ja) 2003-10-03 2007-03-29 ノバルティス アクチエンゲゼルシャフト ミコフェノール酸またはミコフェノール酸ナトリウムを含む医薬多粒子組成物およびラパマイシンとの組み合わせ
CN103845323A (zh) 2012-11-30 2014-06-11 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US5049394A (en) 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
GB0419355D0 (en) 2004-08-31 2004-09-29 Novartis Ag Organic compounds
CN1994295A (zh) 2006-01-06 2007-07-11 华北制药集团新药研究开发有限责任公司 霉酚酸盐的包有肠溶衣的药物组合物
US20100056493A1 (en) 2007-01-25 2010-03-04 Rajesh Jain Modified release pharmaceutical composition and a process of making the same
AU2008288106B2 (en) 2007-08-13 2012-03-15 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
CN101969931A (zh) 2008-03-05 2011-02-09 万能药生物有限公司 包含霉酚酸的调节释放药物组合物及其方法
US20110086102A1 (en) 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
KR20110091252A (ko) * 2010-02-05 2011-08-11 서울대학교산학협력단 미코페놀레이트 모페틸을 함유한 서방성 면역 억제제
CN102793658A (zh) 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
MX2019010829A (es) 2017-03-13 2020-02-05 Okava Pharmaceuticals Inc Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508959A (ja) 2001-10-17 2005-04-07 ノバルティス アクチエンゲゼルシャフト ミコフェノール酸またはミコフェノール酸塩を含む医薬組成物
JP2007507458A (ja) 2003-10-03 2007-03-29 ノバルティス アクチエンゲゼルシャフト ミコフェノール酸またはミコフェノール酸ナトリウムを含む医薬多粒子組成物およびラパマイシンとの組み合わせ
CN103845323A (zh) 2012-11-30 2014-06-11 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
セルセプトカプセル250,医薬品インタビューフォーム,改訂第17版,2013年

Also Published As

Publication number Publication date
CN110662533A (zh) 2020-01-07
WO2018170022A3 (en) 2018-11-08
US11633378B2 (en) 2023-04-25
AU2018236225B2 (en) 2023-11-30
JP2020510691A (ja) 2020-04-09
US20240299343A1 (en) 2024-09-12
US20250049753A1 (en) 2025-02-13
US11786505B2 (en) 2023-10-17
KR20190131036A (ko) 2019-11-25
MX2019010829A (es) 2020-02-05
CA3054817A1 (en) 2018-09-20
BR112019019003A2 (pt) 2020-04-14
US20200030285A1 (en) 2020-01-30
US20190201375A1 (en) 2019-07-04
AU2018236225A1 (en) 2019-09-19
WO2018170022A2 (en) 2018-09-20
EP3595639A2 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
US20240299343A1 (en) Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
RU2609833C2 (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
KR101090719B1 (ko) 프로프라놀롤의 시간조절-지속 방출성 다중-과립형 투여 형태
US9403032B2 (en) Formulations of histone deacetylase inhibitor and uses therof
KR101809305B1 (ko) 다중미립자 l-멘톨 제제 및 관련 방법
RS77904A (sr) Oblik za oralnu primenu teško rastvornih baznih delotvornih supstanci
CN108289848A (zh) 包含urat1的有效抑制剂的药物组合物
JP2005521682A (ja) 結腸放出組成物
WO2011051967A2 (en) Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
CN101094675A (zh) [1,4]二氮杂庚因并[6,7,1-ij]喹啉衍生物制剂
US20200054659A1 (en) Extended release capecitabine capsules
JP2022506007A (ja) ミコフェノール酸活性剤を非ヒト哺乳動物に送達するための方法および組成物
WO2021124264A1 (en) Veterinary formulations comprising rapamycin and methods of using the same for treating animal diseases
Singh et al. Development of biphasic pulsatile release mini-tablets system of poorly water soluble carvedilol phosphate
JP2022515528A (ja) 短時間作用型選択的糖質コルチコイド受容体モジュレーター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7385474

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150